Last updated: February 13, 2026
Overview of NDC 00037-6050
NDC 00037-6050 corresponds to Xyrem (sodium oxybate), manufactured by Jazz Pharmaceuticals. It is prescribed primarily for narcolepsy with cataplexy and other sleep disorders. Approved by the FDA in 2002, Xyrem is considered a high-cost medication due to its complex manufacturing process and regulated distribution under a REMS program.
Market Size and Demand Drivers
Patient Population
- Narcolepsy prevalence: Approximately 0.02–0.05% of the U.S. population suffer from narcolepsy; estimates range from 60,000 to 200,000 patients.
- Treatment penetration: Estimates suggest about 50-60% of diagnosed patients receive Xyrem or other sodium oxybate formulations.
Competitive Landscape
- Primary product: Xyrem remains the dominant sodium oxybate option, with limited competition.
- Alternatives: Sympathomimetics and other wake-promoting agents (e.g., Modafinil, Armodafinil) provide symptomatic relief but do not serve as direct substitutes for Xyrem.
- Pipeline drugs: Limited, with no FDA-approved sodium oxybate competitors in advanced stages.
Market Dynamics
- Market growth: Driven by increased diagnosis and awareness, with an estimated compound annual growth rate (CAGR) of 3-5% over the next five years.
- Pricing structure: High per-unit cost due to strict manufacturing and distribution controls, with a typical wholesale acquisition cost (WAC) of approximately $27,000–$33,000 annually per patient.
- Insurance and reimbursement: Coverage is widespread but often involves prior authorization, impacting adherence and utilization rates.
Historical Price Trends
| Year |
US Wholesale Price (per patient/year) |
Notes |
| 2018 |
~$27,000 |
Stable pricing, consistent with regulatory constraints. |
| 2020 |
~$28,000 |
Slight increase; inflation-adjusted. |
| 2022 |
~$30,000 |
Price escalates due to manufacturing cost inflation and supply chain factors. |
| 2023 |
~$31,500 |
Price plateauing, reflecting market saturation. |
Price Forecast (Next 3-5 Years)
| Year |
Predicted Wholesale Cost (per patient/year) |
Assumption |
| 2024 |
~$32,700 |
3.8% increase, aligned with general inflation. |
| 2025 |
~$33,900 |
Continued inflation; minimal market expansion. |
| 2026 |
~$35,200 |
Stable market saturation; inflation continues. |
Note: Actual patient-level revenue depends on reimbursement, discounts, or capitation agreements.
Strategic Considerations
- Patent and exclusivity: No recent patent exclusivity extensions, but the regulated REMS process maintains barrier to generic competition.
- Pricing leverage: Jazz Pharmaceuticals maintains pricing due to limited alternatives and high treatment costs.
- Market risks: Potential for price regulation, increased competition from pipeline drugs, or policy shifts affecting high-cost drugs.
External Factors Impacting Pricing
- Policy changes: Increased pressure for drug price transparency could influence future pricing strategies.
- Market expansion: Off-label uses or international markets could marginally influence demand and price.
- Manufacturing costs: Complex synthesis and distribution costs drive sustained high prices.
Key Takeaways
- Xyrem remains the leading sodium oxybate therapy, with stable but high pricing driven by regulatory and manufacturing complexities.
- The patient base is small but stable, with slow growth projected at 3-5% annually.
- Pricing in the U.S. remains high, with slight increases likely in the near term due to inflation and supply factors.
- Limited pipeline competition and regulatory barriers protect current pricing levels.
- Market risks include policy shifts targeting high-cost drugs and potential entry of alternative therapies.
FAQs
1. How much does a typical patient pay annually for Xyrem?
Patients often pay between $2,000 to $10,000 annually out-of-pocket, depending on insurance coverage and copayment assistance programs. The wholesale price is around $31,500, but actual costs vary.
2. What factors could influence Xyrem's market size?
Changes in narcolepsy diagnosis rates, regulatory access, off-label use, or the emergence of new therapies could alter market size.
3. Are generic sodium oxybate products available?
No, due to the REMS program and manufacturing complexities, generic sodium oxybate products are not yet available.
4. How has COVID-19 affected Xyrem's sales?
Sales experienced minimal impact; supply chain disruptions were mitigated by strategic stockpiling. Demand remained stable due to the chronic nature of narcolepsy.
5. What regulatory steps could affect future pricing?
Potential legislation targeting drug price transparency, Medicare negotiation rights, or importation policies could impact prices.
References
[1] Jazz Pharmaceuticals. Xyrem (sodium oxybate) prescribing information. 2022.
[2] IQVIA. National Prescription Audit. 2022.
[3] FDA. Narcolepsy treatments and drug approvals overview. 2023.
[4] MarketWatch. "Sodium oxybate (Xyrem) market analysis." 2023.
